New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
08:07 EDTMYL, ACTActavis announces agreement related to Generess FE patent challenge litigation
Actavis (ACT) announced that it has entered into an agreement with Mylan (MYL) and Famy Care to settle all outstanding patent litigation related to Mylan's generic version of Generess. Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of Generess® FE under its pending Abbreviated New Drug Application beginning on April 1, 2015. Alternatively, Mylan will be permitted to launch an authorized generic version of Actavis' product beginning on October 1, 2015. Other terms of the settlement were not disclosed. Actavis remains in litigation with Lupin Ltd in connection with Lupin's pending ANDA for a generic version of Generess.
News For ACT;MYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 9, 2015
11:50 EDTMYLPerrigo releases full statement of Abbott CEO regarding Mylan stake
Subscribe for More Information
07:53 EDTMYLMylan to hold a conference call for Perrigo shareholders
Subscribe for More Information
October 7, 2015
09:35 EDTMYLMylan potential acquisition of Perrigo looks questionable says Bernstein
Subscribe for More Information
October 5, 2015
10:02 EDTMYLBofa/Merrill healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
September 30, 2015
14:58 EDTMYLMylan volatility at 52-week high
Mylan October weekly put option implied volatility is at 70, October is at 57, November is at 54; compared to its 52-week range of 26 to 58, suggesting large price movement.
11:06 EDTMYLStocks with call strike movement; FSLR MYL
First Solar (FSLR) January 50 call option implied volatility decreased 5% to 47, Mylan (MYL) January 47 call option implied volatility increased 4% to 48 according to IVolatility.
September 29, 2015
12:35 EDTMYLPerrigo shareholders pressure company to explore sale, Reuters says
Certain Perrigo (PRGO) shareholders have requested that company explore a sale, hoping for an alternative to Mylan's (MYL) approximately $25B hostile bid, Reuters reports, citing people familiar with the matter. The pressure represents a challenge to Perrigo's defense strategy, the report says. Some of the company's shareholders view Novartis (NVS), Sanofi (SNY), Procter & Gamble (PG), and Colgate-Palmolive (CL) as potential suitors, the report says. Reference Link
September 28, 2015
07:31 EDTMYLMylan launches generic Invega tablets
Subscribe for More Information
07:27 EDTMYLFDA and the Parental Drug Association to co-host a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use